BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Alzheimer's Expert Leaked Inside Information on Elan Corporation PLC (ELN), Wyeth (WYE) Drug


11/21/2012 8:11:29 AM

In yet another case of insider trading to unnerve the pharmaceutical industry, federal prosecutors have cited a leading Alzheimer’s expert, who chaired the safety monitoring committee for the 2008 trial of the ‘bapi’ drug that was developed by Wyeth and Elan, as a tipster in what is being called the “most lucrative insider trading scheme ever charged.” The feds say that University of Michigan neurology professor Sid Gilman, a prominent expert on various neurological disorders, provided inside information about the Phase II clinical trial of the Alzheimer’s drug to Mathew Martoma, a former trader at CR Intrinsic, which a division of SAC Capital, and who was charged with making about $276 million in combined profits and avoided losses. According to a complaint filed in federal court by the US Securities and Exchange Commission, Gilman, 80, and Martoma were in contact from mid-2006 through mid-2008, when Gilman served not only as a consultant to the drugmakers, but also as a consultant to a so-called expert network that linked money managers with experts in different industries. Court documents indicate Martoma sought insights from Gilman during 42 separate paid consultations. Gilman, who was chosen to present Phase II trial results at the International Conference on Alzheimer’s in July 2008, first fed Martoma about upbeat data and then information that the trial failed to meet its primary endpoint, the complaint alleges.

Read at Pharmalot
Read at Reuters
Read at Forbes
Read at SF Gate
Read at The Day

Pharmalot
Reuters
Forbes
SF Gate
The Day
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->